Mary Kathleen Flynn

Kohlberg & Co-backed pharma CDMO expected to take recap bids; check out Infrastructure Investor Deals and PERE Deals

A scoop about Kohlberg & Company seeking recap bids for a pharmaceutical CDMO in its portfolio. Also today, we’re showcasing two new deal-focused websites from PEI Group that are sure to appeal to PE Hub’s dealmaking audience.

GP stake strategy represents the best of both worlds, says HPC’s Conway Bate

Hunter Point Capital has acquired stakes in Pretium Partners, Coller Capital, Inflexion, L Catterton and The Vistria Group.

Hunter Point Capital makes the case for GP stakes; single-asset CVs surged in 2024

PE Hub highlights Hunter Point Capital.

Cordillera co-founder Ashley Marks makes the case for 'weird stuff'

'Investments in niche, non-correlated assets are often smaller in scale, less competitive, and outcomes tend to be more dependent on idiosyncratic factors such as the supply chain for whiskey, the price of carbon, or federally insured crop insurance.'

KKR countersues DOJ, FTC, arguing ‘classic case study of government agency overreach’

The KKR complaint says: 'Now, on the eve of a leadership transition, the Antitrust Division has threatened a final act of agency overreach: the imposition of draconian and grossly disproportionate penalties on KKR based on alleged premerger paperwork errors that were immaterial to antitrust clearance.'

'Managers are starting to get cracking,' says Cambridge Associates’ Andrea Auerbach in a 2025 Outlook Q&A; deal announcements pick up

Palm Peak acquires Pacific Shoring Products.

Cambridge Associates' Andrea Auerbach: 'After 10 long quarters, we are back in positive territory for buyouts'

'There are half a trillion dollars in distributions that should have happened by now. LPs have been reminding GPs of this fact for a while, increasing pressure for more exits in 2025.'

Churchill's Anne Philpott: 'Investors will flock to junior capital to lock in long-term, fixed rate return stability'

'Junior capital offers delayed draw capacity, which is a critical source of funding for sponsors with buy-and-build investment strategies seeking to make post-closing acquisitions.'

Luminate Capital founder Hollie Haynes: 'We have changed the private equity model'

'We focus on growth not cost cuts. This is a win for all parties. It’s liquidity much faster and easier than an IPO. It’s partnership with a growth investor.'

'Investors are climbing out of their foxholes,' say The Riverside Company co-CEOs; plus Deal of the Year Awards nominations due Friday

Private equity leaders express cautious optimism for 2025.